TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

– Proven to deliver significant and robust triglyceride reductions – – Only treatment for sHTG indicated to reduce the risk of acute pancreatitis – – Ionis’ first independent commercial launch in a prevalent condition – – Ionis to host webcast today at 3:30 p.m. ET – CARLSBAD, Calif.